CD19靶向CAR-T治疗后成人异基因造血干细胞移植的安全性
该研究回顾了32例接受CD19 CAR-T治疗后进行异基因造血干细胞移植的成人患者(ALL 19例,NHL/CLL 13例),重点观察移植后毒性。结果显示3-4级急性GVHD累积发生率25%,慢性GVHD 10%,100天和1年非复发死亡率在ALL患者分别为16%和21%,在NHL/CLL患者分别为15%和33%。毒性未超过该高危人群的预期发生率。
要点
- CAR-T后allo-HCT的3-4级急性GVHD发生率为25%,慢性GVHD为10%。
- ALL患者CAR-T后较晚移植与较高死亡率相关。
- NHL/CLL患者接受清髓性预处理与较高死亡率相关。
核心结论
- CAR-T治疗后进行异基因移植的毒性未超过该高危人群的预期发生率。
研究设计与样本
- 回顾性研究,纳入32例接受CD19 CAR-T治疗后进行异基因造血干细胞移植的成人患者,其中ALL 19例,NHL/CLL 13例。
主要发现
- 3-4级急性GVHD和慢性GVHD的累积发生率分别为25%和10%。
- 所有患者均实现中性粒细胞植入(中位18.5天),除3例外均实现血小板植入(中位12天)。
- 22%的患者在移植后100天内发生病毒或系统性真菌感染。
- ALL患者100天和1年非复发死亡率累积发生率分别为16%和21%,NHL/CLL患者分别为15%和33%。
- 在ALL患者中,CAR-T后较晚进行移植与较高死亡率相关;在NHL/CLL患者中,清髓性预处理与较高死亡率相关。
临床怎么用
- 对于CAR-T治疗后考虑异基因移植的患者,需评估移植时机及预处理强度对死亡率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (allo-HCT) is offered to selected patients after chimeric antigen receptor-modified T-cell (CAR-T) therapy. Lymphodepleting chemotherapy and CAR-T therapy have immunosuppressive and immunomodulatory effects that could alter the safety profile of subsequent allo-HCT. We reviewed our experience with 32 adults (acute lymphoblastic leukemia [ALL], n = 19; B-cell non-Hodgkin lymphoma [NHL]/chronic lymphocytic leukemia [CLL], n = 13) who received an allo-HCT after CAR-T therapy, with a focus on posttransplant toxicities. Myeloablative conditioning (MAC) was used in 74% of ALL patients and 39% of NHL/CLL patients. The median time from CAR-T therapy to allo-HCT was 72 days in ALL patients and 122 days in NHL/CLL patients. Cumulative incidences of grade 3-4 acute graft-versus-host disease (GVHD) and chronic GVHD were 25% and 10%, respectively. All patients had neutrophil recovery (median, 18.5 days) and all but 3 had platelet recovery (median, 12 days). Twenty-two percent had viral or systemic fungal infection within 100 days after allo-HCT. The 100-day and 1-year cumulative incidences of NRM were 16% and 21%, respectively, for ALL patients and 15% and 33%, respectively, for NHL/CLL patients. In ALL patients, later utilization of allo-HCT after CAR-T therapy was associated with higher mortality. In NHL/CLL patients, MAC was associated with higher mortality. Toxicities did not exceed the expected incidences in this high-risk population.
引用
- Shadman M, Gauthier J, Hay KA, et al. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv. 2019. PMID: 31648329. doi:10.1182/bloodadvances.2019000593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。